Inside the research
Omnicell, Inc.
OMCL Research profile · latest available data
Price overview
$33.66
▲ +0.63 (+1.9%)
| 52w hi | $51.39 |
|---|---|
| 52w lo | $29.46 |
| Vol | 508.40K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.38
| Short | -0.72 |
|---|---|
| Medium | -0.30 |
| Long | +0.15 |
computed 2026-09-27
Key fundamentals
Omnicell, Inc.
Healthcare · Health Information Services
| Market cap | $1.53B |
|---|---|
| Enterprise value | $1.44B |
| Trailing P/E | 40.07x |
| Forward P/E | 16.11x |
| EV / EBITDA | 17.56x |
| P / S (ttm) | 1.23x |
| Profit margin | 3.1% |
| Return on equity | 3.1% |
| Revenue growth | +7.5% |
| Earnings growth | +333.3% |
| Debt / equity | 15.48 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.28 | |
| Sector | +0.08 | |
| Technical | -0.50 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Risk Metrics
| Beta vs SPX | 0.99 |
|---|---|
| Corr SPX | 0.31 |
| Annual vol | 51.7% |
| Annual ret | -1.2% |
| Sharpe | -0.02 |
| Max DD | -53.6% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-07-01 | Officer / Director Change, Exhibits | read |
| 2026-05-26 | Officer / Director Change, Bylaws Amendment… | read |
| 2026-04-28 | Earnings Release, Exhibits | read |
| 2026-02-05 | Earnings Release, Exhibits | read |
| 2025-12-08 | Reg FD Disclosure, Exhibits | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-10-06 | Bylaws Amendment, Exhibits | read |
| 2025-08-25 | Officer / Director Change, Exhibits | read |
| 2025-07-31 | Earnings Release, Exhibits | read |
| 2025-06-05 | Officer / Director Change, Exhibits | read |
| 2025-05-23 | Officer / Director Change, Shareholder Vote… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-15 | LIPPS RANDALL A | Director, Officer, CHAIRM | Sell | 10.00K | $470.00K |
| 2026-07-01 | Njoku Nnamdi | Officer, President & COO | Grant | 12.31K | — |
| 2026-06-01 | Voynick Eileen J. | Director | Grant | 4.79K | — |
| 2026-06-01 | Seim Robin Gene | Director | Grant | 4.84K | — |
| 2026-06-01 | Scott Bruce E | Director | Grant | 4.63K | — |
| 2026-06-01 | Bousa Edward Peter | Director | Grant | 4.60K | — |
| 2026-06-01 | Bauer Joanne B | Director | Grant | 5.03K | — |
| 2026-06-01 | PARRISH MARK W | Director | Grant | 4.84K | — |
| 2026-06-01 | Ghoshal Kaushik | Director | Grant | 4.60K | — |
| 2026-06-01 | Garrett Mary | Director | Grant | 5.03K | — |
Flow & Concentration
| Insider 180d net | -$470.00K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.15B | +11.6% | |
| Gross profit | $503.44M | +11.8% | |
| Operating income | -$34.87M | +8.2% | |
| Net income | -$20.37M | -2.1% | |
| Cash from ops | $181.09M | +14.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $33.05 | $33.73 | $32.63 | $33.66 | 508.40K |
| Sep 24 | $33.01 | $33.23 | $32.60 | $33.03 | 499.20K |
| Sep 23 | $33.17 | $33.58 | $32.40 | $32.99 | 437.00K |
| Sep 22 | $32.86 | $33.47 | $32.72 | $33.17 | 547.20K |
| Sep 21 | $32.43 | $32.57 | $31.98 | $32.43 | 434.90K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →